The idea of evidence-based guidelines has been around for quite a while. One of their big problems has been that the “evidence” tends to change, often dramatically, and that population-based guidelines are at odds with our increasing understanding that there is wide biochemical variation across individuals. (NEJM Article) High blood pressure is one of the most common chronic conditions and many guidelines regarding its treatment have been promulgated. The most recent “consensus” guidelines were released in 2014. The authors attempted to estimate the effects of treating all patients according to this guideline, which focuses more on diastolic rather than systolic blood pressure for adults under 60, has a higher blood pressure goal for adults 60 or older or for patients with diabetes or chronic kidney disease. (These changes were made because the former “evidence-based” guidelines were causing significant harm to many patients.) Using a model that attempted to ascertain how many people would be treated under the guideline compared to how many are actually receiving treatment now, and assuming the treatment would be effective, what different outcomes would be achieved. About 860,000 more people who have been diagnosed with heart disease or high blood pressure would be treated each year from 2014 to 2024 and an additional 8.6 million who have hypertension but not heart disease would also be treated each year. All this new treatment would prevent about 13,000 deaths a year and 56,000 cardiovascular events a year. For some groups the treatment was found to be cost-saving; i.e. the costs of treatment would be outweighed by the savings in prevented medical care, but it is not clear that the researchers added all the costs from people living longer. For other groups, it would be cost-effective, which means it would add to health care spending, but would be worth it in terms of more years of life for the patients. Treating everyone with high blood pressure who should be treated is a worthy goal, but I am dubious about “modeled” results, and you have to be a little leery of the staying power of any guideline.
The Cost of Hypertension Guideline Compliance
By Kevin RocheFebruary 19, 2015Commentary
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
Another example of over-priced companies trying to find some way to survive in the post-epidemic financial world. Transcarent, which does something, somehow to “access high quality, affordable care” is buying...
March 6, 2023
In an attempt to swiftly revive two floundering health care companies, a PE firm has announced the merger and recapitalization of Revive Health and SwiftMD. You know they are...
January 30, 2023
Investors have not yet learned their lesson, as Pearl Health gathers a new round of $75 million in capital for its business of supporting physicians who want to participate in...
January 30, 2023
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace
March 21, 2023
Minnesota’s New Energy Insanity, Part 7
Minnesota is a particularly poor place to rely on solar power, but other states aren't…
March 21, 2023
A Quick SVB Follow-up
As I suspected, the SVB saga is primarily one of regulatory malfeasance, coupled with political…
March 19, 2023
Tom Frieden Speaks in the WSJ
A public health expert writes an article for the WSJ which amply demonstrates why Americans…